Intractable myoclonic seizures in an allogeneic stem cell transplant recipient

A rare case of myoclonic epilepsy

Anna Robuccio, Paddy Ssentongo, Michael Sather, David Claxton, Frank G. Gilliam

Research output: Contribution to journalArticle

Abstract

Introduction: Myoclonus may be a rare complication of stem cell transplant but has limited discussion in the scientific literature. Case: We present a case of an acute myeloid leukemia survivor who developed refractory myoclonic epilepsy four years after graft versus host disease (GVHD) developed six days following matched unrelated allogeneic hematopoietic stem cell transplant. Discussion: Graft versus host disease occurs in 30-50% of allogenic hematopoietic stem cell transplant patients and may cause pharmacoresistant myoclonic epilepsy; however, the mechanisms by which GVHD leads to recurrent myoclonic seizures are not well understood (Lee, 2005) [1]. The paucity of clinical reports of such manifestation makes it difficult to diagnose and effectively manage these patients.

Original languageEnglish (US)
Pages (from-to)48-51
Number of pages4
JournalEpilepsy and Behavior Case Reports
Volume4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Myoclonic Epilepsy
Graft vs Host Disease
Seizures
Stem Cells
Hematopoietic Stem Cells
Transplants
Literature
Myoclonus
Acute Myeloid Leukemia
Survivors
Transplant Recipients

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

@article{2bbe8395d22743efabac443b2050ee41,
title = "Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy",
abstract = "Introduction: Myoclonus may be a rare complication of stem cell transplant but has limited discussion in the scientific literature. Case: We present a case of an acute myeloid leukemia survivor who developed refractory myoclonic epilepsy four years after graft versus host disease (GVHD) developed six days following matched unrelated allogeneic hematopoietic stem cell transplant. Discussion: Graft versus host disease occurs in 30-50{\%} of allogenic hematopoietic stem cell transplant patients and may cause pharmacoresistant myoclonic epilepsy; however, the mechanisms by which GVHD leads to recurrent myoclonic seizures are not well understood (Lee, 2005) [1]. The paucity of clinical reports of such manifestation makes it difficult to diagnose and effectively manage these patients.",
author = "Anna Robuccio and Paddy Ssentongo and Michael Sather and David Claxton and Gilliam, {Frank G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.ebcr.2015.06.005",
language = "English (US)",
volume = "4",
pages = "48--51",
journal = "Epilepsy and Behavior Case Reports",
issn = "2213-3232",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Intractable myoclonic seizures in an allogeneic stem cell transplant recipient

T2 - A rare case of myoclonic epilepsy

AU - Robuccio, Anna

AU - Ssentongo, Paddy

AU - Sather, Michael

AU - Claxton, David

AU - Gilliam, Frank G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Myoclonus may be a rare complication of stem cell transplant but has limited discussion in the scientific literature. Case: We present a case of an acute myeloid leukemia survivor who developed refractory myoclonic epilepsy four years after graft versus host disease (GVHD) developed six days following matched unrelated allogeneic hematopoietic stem cell transplant. Discussion: Graft versus host disease occurs in 30-50% of allogenic hematopoietic stem cell transplant patients and may cause pharmacoresistant myoclonic epilepsy; however, the mechanisms by which GVHD leads to recurrent myoclonic seizures are not well understood (Lee, 2005) [1]. The paucity of clinical reports of such manifestation makes it difficult to diagnose and effectively manage these patients.

AB - Introduction: Myoclonus may be a rare complication of stem cell transplant but has limited discussion in the scientific literature. Case: We present a case of an acute myeloid leukemia survivor who developed refractory myoclonic epilepsy four years after graft versus host disease (GVHD) developed six days following matched unrelated allogeneic hematopoietic stem cell transplant. Discussion: Graft versus host disease occurs in 30-50% of allogenic hematopoietic stem cell transplant patients and may cause pharmacoresistant myoclonic epilepsy; however, the mechanisms by which GVHD leads to recurrent myoclonic seizures are not well understood (Lee, 2005) [1]. The paucity of clinical reports of such manifestation makes it difficult to diagnose and effectively manage these patients.

UR - http://www.scopus.com/inward/record.url?scp=84938775745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938775745&partnerID=8YFLogxK

U2 - 10.1016/j.ebcr.2015.06.005

DO - 10.1016/j.ebcr.2015.06.005

M3 - Article

VL - 4

SP - 48

EP - 51

JO - Epilepsy and Behavior Case Reports

JF - Epilepsy and Behavior Case Reports

SN - 2213-3232

ER -